In­ject­ed form of Leqem­bi ap­pears ef­fec­tive at clear­ing amy­loid, but with no­table risks

New da­ta on an in­jectable form of Ei­sai’s Alzheimer’s drug, Leqem­bi, showed that it was more ef­fec­tive than an in­tra­venous ver­sion at clear­ing amy­loid but al­so came with a high­er risk of brain-re­lat­ed side ef­fects known as ARIA.

The study, which was pre­sent­ed at the Clin­i­cal Tri­als on Alzheimer’s Dis­ease con­fer­ence in Boston, looked at pa­tients who got week­ly sub­cu­ta­neous in­jec­tions of Leqem­bi as an al­ter­na­tive to every-oth­er-week in­tra­venous in­fu­sions. The da­ta come from a six-month look at the study, and Ei­sai aims to sub­mit the for­mu­la­tion for ap­proval once it has a year’s worth of re­sults by the end of March 2024, ac­cord­ing to Michael Irizarry, Ei­sai’s head of clin­i­cal neu­rol­o­gy re­search and deputy chief clin­i­cal of­fi­cer.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER